Displaying 241 - 243 of 243
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: β-human chorionic gonadotropin
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Talwar Research Foundation, Indian Council for Medical Research
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 1 - 10 of 70
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Adenylate Cyclase 10 and cyclic adenosine monophopshate, sAC and cAMP, soluble adenylyl cyclase
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Alternative Name: Mullerian-inhibiting Substance (MIS), Mullerian-inhibiting Hormone (MIH), Mullerian-inhibiting Factor (MIF), Mullerian Duct Inhibitory Factor (MDIF), Mullerian Regression Factor (MRF), Anti-paramesonephric Hormone (APH)
Development Stage: Lead Optimization
Alternative Name: Astacin Like Metalloendopeptidase, Ovastacin, Sperm Acrosomal SLLP1 Binding, SAS1B, Oocyte Astacin, EC 3.4
Target
User: Female
Hormonal: No
Development Stage: Target Validation

Pages

Displaying 41 - 50 of 121
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Oral
Developer: WHO, South-to-South Cooperation in Reproductive Health
Development Stage: Phase I
Alternative Name: SARM C-6
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: GTx, Inc., Memphis, TN
Development Stage: Pre-clinical
Alternative Name: H2-GMZ
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: Injectable Gestodene (GES) + Ethinyl Estradiol (EE)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Peking University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Stanford University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of California San Diego
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: KYDES Pharmaceuticals, FHI 360
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of Tennessee Health Sciences Center
Development Stage: Pre-clinical
Alternative Name: Gendarussa
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Airlangga University, Indopharma, FHI 360
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: ContraMed, LLC
Development Stage: Phase II

Pages

Displaying 31 - 40 of 52
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: Marketed
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited
Development Stage: SRA/WHO PQ Approved

Pages

CSV